On Sunday, April 20th 2025, starting 8:30am GMT, there will be maintenance work that will involve the website being unavailable during parts of the day. We apologize for any inconvenience this may cause and appreciate your understanding.
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Epidemiology and Risk Factors
-
41 min
1. The changing prevalence of asthma- Dr. Deborah Jarvis
-
29 min
2. Recent advances in asthma genetics- Prof. Miriam Moffatt
-
35 min
3. Asthma: an epidemic caused by epigenetics?- Prof. David Schwartz
-
30 min
4. Role of the microbiota in asthma- Prof. B. Brett Finlay
-
32 min
5. Diet and asthma- Prof. Lewis Smith
-
43 min
6. Obesity and asthma- Prof. Anne Dixon
-
35 min
7. Occupational asthma: management beyond the textbooks- Prof. Paul Cullinan
- Clinical Phenotypes
-
42 min
8. The origins of asthma- Prof. Peter Sly
-
46 min
9. Pre-school wheeze- Prof. Andrew Bush
-
50 min
-
24 min
11. Smoking asthmatics- Prof. Neil Thomson
-
27 min
12. Aspirin exacerbated respiratory disease- Prof. Chris Corrigan
- Mechanisms of Asthma
-
48 min
13. Advances in asthma: airway inflammation- Prof. William Busse
-
48 min
14. The role of mast cells in asthma- Prof. Peter Bradding
-
67 min
15. Dendritic cells in asthma- Prof. Bart Lambrecht
-
30 min
16. The airway smooth muscle in asthma- Prof. Judith Black
-
49 min
17. Role of virus infection in asthma 1- Prof. Sebastian Johnston
-
27 min
18. Role of virus infection in asthma 2- Prof. Sebastian Johnston
-
51 min
19. Severe asthma: characterisation, mechanisms & treatment- Prof. Fan Chung
-
46 min
20. Steroid resistance in asthma: mechanisms and potential therapies- Prof. Ian Adcock
-
26 min
21. Macrophage in asthma- Prof. Douglas Robinson
- Diagnosis of Asthma
-
70 min
22. Physiology of asthma and involvement of small airways- Prof. Charles G. Irvin
-
27 min
23. Induced sputum in asthma- Prof. Antonio Spanevello
-
61 min
- Therapy and Management
-
41 min
25. Pulmonary drug delivery- Prof. Anthony J. Hickey
-
32 min
26. The management of chronic asthma- Prof. Mark Fitzgerald
-
21 min
27. Inhaled corticosteroids and beta2-agonists- Dr. Omar S. Usmani
-
20 min
28. Management of "difficult asthma"- Prof. Elisabeth Bel
-
47 min
29. Management of acute exacerbations of asthma- Dr. Chris Fanta
-
34 min
30. Non-pharmacological treatments for asthma- Prof. Neil Thomson
-
45 min
31. Asthma: beyond the prescription- Prof. Martyn Partridge
-
45 min
32. New drugs for asthma- Prof. Peter Barnes
-
24 min
33. Anti-IgE therapy for asthma- Dr. Andrew Menzies-Gow
- Archived Lectures *These may not cover the latest advances in the field
-
45 min
34. New drugs for asthma- Prof. Peter Barnes
-
35 min
35. Asthma phenotypes in children- Prof. Andrew Bush
-
40 min
36. Steroid resistance in asthma: mechanisms and potential therapies- Prof. Ian Adcock
-
42 min
37. Severe asthma in children- Prof. Andrew Bush
Printable Handouts
Navigable Slide Index
- Introduction
- Active smoking and asthma
- Prevalence rates for active smoking in asthma
- Poor asthma control in smokers
- Chronic mucus hypersecretion in smokers
- Health care utilization in smokers with asthma
- Age-related decline in FEV1 in smokers
- Persistent airflow obstruction, smoking & asthma
- Reduced sensitivity to inhaled steroids
- Impaired response to inhaled fluticasone
- Impaired response to oral prednisolone
- Corticosteroids sensitivity
- Mechanisms of adverse effects
- Non-eosinophilic inflammatory phenotype
- Elevated induced sputum neutrophil count
- Neutrophilic inflammatory phenotype
- Increased bronchial biopsy mast numbers
- Smokers with asthma-airway inflammation
- Mechanisms for corticosteroid insensitivity
- Molecular mechanisms of steroid resistance
- Management of smoking asthmatics
- Clinical benefits of smoking cessation
- Stepwise management of chronic asthma (1)
- Change in post-BD FEV1
- Stepwise management of chronic asthma (2)
- Impaired response to inhaled beclomethasone
- Combination therapy: ICS + LABA
- Leukotriene receptor antagonist
- Tiotropium
- Potential therapies for smokers with asthma
- Restoration of corticosteroid sensitivity
- Low dose theophylline & inhaled steroid
- PPAR- gamma agonists
- PPAR-gamma agonist - rosiglitazone
- Change in FEV1 with rosiglitazone
- Potential anti-inflammatory effects of statins
- Exploratory clinical trial of atorvastatin
- Atorvastatin in smokers with asthma (1)
- Atorvastatin in smokers with asthma (2)
- Conclusions: clinical
- Conclusions: mechanisms
- Conclusions: management
- Acknowledgements
- References (1)
- References (2)
- References (3)
- References (4)
Topics Covered
- High prevalence rates of smoking in asthma
- Detrimental effects of smoking on clinical outcomes
- Impaired response to corticosteroids
- Mechanisms of adverse effects
- Management includes smoking cessation, but optimum drug therapy not established
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Thomson, N. (2011, December 29). Smoking asthmatics [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 19, 2025, from https://doi.org/10.69645/GOUV1183.Export Citation (RIS)
Publication History
- Published on December 29, 2011
Financial Disclosures
- Prof. Neil Thomson, Grant/Research Support (Principal Investigator): Boston Scientific makes of the Alair system for bronchial thermoplasty: industry sponsored grant funding to the University of Glasgow for clinical trial work.
Smoking asthmatics
Published on December 29, 2011
24 min
